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BRIEF DEFINITIVE REPORT
        Experimental autoimmune encephalomyelitis 
(EAE) is an infl  ammatory demyelinating disease 
of the central nervous system (CNS) induced in 
laboratory animals by active immunization with 
myelin antigens or by the adoptive transfer of 
myelin-specifi  c CD4  +   T cells. It is widely used 
as an animal model of multiple sclerosis (MS) and 
as a prototype of organ-specifi  c autoimmunity. 
Until recently, EAE and MS were considered 
Th1 diseases, mediated by IL-12p70  –  polarized, 
IFN-      –  producing eff  ector cells. This impres-
sion was based, in large part, on the association 
between clinical disease activity and expression of 
IFN-     and IL-12p40 (a subunit of IL-12p70) in 
CNS tissues, cerebrospinal fl  uid, and   circulating 
leukocytes ( 1  –  3  ). In addition, activated macro-
phages are the predominant leukocyte in CNS 
infi  ltrates of affl   icted animals and patients, similar 
to the infi  ltrates that characterize Th1-dependent 
hypersensitivity and antimicrobial responses in 
the periphery (  4, 5  ). 
  Recent fi  ndings, however, suggest that the 
cytokine pathways underlying encephalito-
genic T cell development and function are more 
complex than previously appreciated. Defi  ciency 
of IL-17 or IL-23 (a heterodimeric monokine 
composed of IL-12p40 and p19 chains that ex-
pands and/or stabilizes Th17 cells) (  6, 7  ) con-
fers partial or complete resistance, respectively, 
against MOG  35-55    –  induced EAE in C57BL/6 
mice, whereas defi  ciency of IFN-    or IL-12p70 
does not (  8  –  10  ). Furthermore, myelin-specifi  c 
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histopathological features and immune profi  les. IL-12p70  –  driven disease was characterized 
by macrophage-rich infi  ltrates and prominent NOS2 up-regulation, whereas neutrophils 
and granulocyte  –  colony-stimulating factor (CSF) were prominent in IL-23  –  driven lesions. 
The monocyte-attracting chemokines CXCL9, 10, and 11 were preferentially expressed in 
the CNS of mice injected with IL-12p70  –  modulated T cells, whereas the neutrophil-at-
tracting chemokines CXCL1 and CXCL2 were up-regulated in the CNS of mice given IL-23  –
  modulated T cells. Treatment with anti  –  IL-17 or anti  –  granulocyte/macrophage-CSF 
inhibited EAE induced by transfer of IL-23  –  polarized, but not IL-12p70  –  polarized, cells. 
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as an ascending paralysis, in 100% of hosts. Peak and cumulative 
disease scores and rate of disability progression were similar 
between the two groups (  Fig. 1 C  ). 
  Patterns of CNS infi  ltration and proinfl  ammatory molecule 
expression distinguish EAE induced by IL-23  –   versus 
IL-12p70  –  modulated cells 
  There was no signifi  cant diff  erence in the number of CNS-
infi  ltrating cells per mouse when comparing recipients of 
IL-12  –   and IL-23  –  modulated cells. CNS mononuclear cells 
from host mice that received IL-12p70  –  modulated cells con-
sisted almost exclusively of IFN-     producers, indicating that 
the donor cells had maintained a Th1 phenotype after adop-
tive transfer (  Fig. 2, A and B  ).   Conversely, the majority of 
Th17 cell lines that have been expanded with IL-23 are 
effi   cient autoimmune eff  ector cells (  11  ). Collectively, these 
observations invite an alternative interpretation of the mech-
anism of action of IL-12p40 in neuroinfl  ammation; namely, 
that its role is in the production of IL-23 and reinforce-
ment of the Th17 eff  ector cell population, rather than (or in 
addition to) the production of IL-12p70 and promotion of 
Th1 diff  erentiation. 
  Some investigators have assumed that the newly recog-
nized importance of IL-23/Th17-dependent events in at least 
some forms of EAE negates the formerly favored model of 
pathogenesis that highlights IL-12p70/Th1-driven pathways. 
However, we and others have demonstrated that IL-12p70, 
as well as IL-23, directly promotes encephalitogenicity be-
cause ordinarily innocuous lineage-uncommitted or tolerized 
myelin-specifi  c T cells acquire the ability to transfer dis-
ease after antigenic challenge in the presence of recombinant 
IL-12p70 (  12, 13  ). This suggests that myelin-specifi  c cells, 
cultured under conditions that favor the development of either 
Th1 or Th17 cells, are capable of mediating similar clinical 
syndromes, most likely via engagement of distinct proinfl  am-
matory pathways. 
  Indeed, here we show that IL-12  –   and IL-23  –  modulated 
T cell lines, derived from proteolipid protein (PLP)  139  –  151  /
IFA-primed SJL donors, trigger a clinically indistinguishable 
myelopathy upon transfer into naive syngeneic hosts. Despite 
their similarities, the disease induced by each of these cell 
lines diff  ers in CNS chemokine expression patterns as well as 
in the extent of optic nerve involvement and the composi-
tion and positioning of infi  ltrating leukocytes within the spinal 
cord at peak disability. Of greater therapeutic relevance, the 
two forms of EAE diff  er in responsiveness to specifi  c immuno-
modulatory interventions. 
    RESULTS AND DISCUSSION   
  IL-12p70  –   and IL-23  –  polarized T cells induce EAE 
after adoptive transfer 
  We harvested draining LN cells (LNCs) from SJL mice that 
had been primed with PLP  139  –  151   in IFA and cultured them 
with antigen under either neutral conditions (i.e., with antigen 
and an anti  –  IL-12p40  –  neutralizing antibody), or conditions 
favorable to the generation of Th17 (IL-23, IL-1    , anti  –  IL-4, 
and anti  –  IFN-    ), or Th1 (IL-12p70, IFN-    , anti  –  IL-4, and 
anti  –  IL-23p19) cells. Cells cultured with IL-12p70 up-regu-
lated the Th1-associated transcription factor, T-bet, and 
secreted IFN-     and no detectable IL-17 during a 4-d primary 
culture. In contrast, cells stimulated with IL-23 up-regulated 
the Th17-associated transcription factor, ROR   t, and secreted 
large quantities of IL-17 and relatively small quantities of IFN-     
(  Fig. 1, A and B  ).   Cells from all three groups proliferated and 
secreted IL-2 to a comparable extent in response to antigenic 
stimulation (not depicted).     As we have previously reported 
(  13  ), PLP/IFA-primed LNCs failed to transfer EAE to naive 
syngeneic hosts after culture with antigen and anti  –  IL-12p40 
or antigen alone. In contrast, cells stimulated with antigen and 
either IL-12 or IL-23 reproducibly induced EAE, manifested 
    Figure 1.         IL-12  –   and IL-23  –  modulated myelin-specifi  c T cells 
induce EAE in naive hosts.   (A)  PLP 139 – 151  /IFA-primed T cells were cul-
tured with antigen under conditions favorable to the generation of Th1 
cells (IL-12, IFN-   ,     IL-4, and     IL-23p19), Th17 cells (IL-23, IL-1,    IFN-  , 
and     IL-4), or lineage-uncommitted cells (    IL-12p40). Supernatants were 
harvested every 24 h and analyzed by ELISA. (B) RNA was extracted at 96 h 
from LNC cultures as described in A for measurement of transcription 
factors by real-time RT-PCR. Levels were normalized to GAPDH. The data 
are shown as fold induction over the level in cells cultured under neutral 
conditions. (C) Purifi  ed T cells from IL-12  –   and IL-23  –  modulated cultures 
were transferred to naive syngeneic recipients (25   ×   10  6   cells/mouse). 
Mice were killed at peak disease for histological analysis. The data shown 
are representative of four independent experiments. Asterisks indicate a 
signifi  cant difference when compared with the control group. *, P   <   0.05 
compared with recipients of lineage uncommitted T cells.     JEM VOL. 205, July 7, 2008  1537
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A signifi  cant subpopulation of MHC class II        CD115        
Ly6G  +   7/4  +   leukocytes was present among the CNS mono-
nuclear fraction isolated from recipients of IL-23  –  modulated, 
but not IL-12  –  modulated, cells (  Fig. 3 A, C, and D  ).   The 
identifi  cation of these cells as neutrophils was corroborated 
by cytospin preparation and Giemsa staining after FACS sort-
ing (not depicted). The accumulation of neutrophils in the 
CNS was intriguing because granulocytes have been shown 
to play a critical role in EAE induced by active immunization 
in SJL mice and to increase blood  –  brain barrier permeability 
in other models of neuroinfl  ammation (  14, 15  ). Spinal cords 
from recipients of IL-23  –  modulated cells expressed elevated 
levels of G-CSF, a neutrophil activation and growth factor 
(  Fig. 4 C  ).   G-CSF was detectable in the sera of mice with 
IL-23  –  driven EAE at peak disease, but not in the sera of mice 
with EAE mediated by IL-12  –  modulated cells (unpublished 
data). Interestingly, G-CSF mRNA has been detected in MS 
lesions, and administration of recombinant G-CSF has been 
associated with acute MS fl  ares in patients undergoing bone 
marrow transplantation (  16, 17  ). 
  In contrast, CNS-infi  ltrating cells from the recipients of 
IL-12  –  modulated cells were composed almost exclusively of 
monocytes and lymphocytes. Spinal cords from these mice con-
tained a higher percentage and absolute number of MHC class II  +   
CNS mononuclear cells from recipients of IL-23  –  modulated 
cells secreted IL-17 (at a 30-fold higher frequency over recip-
ients of IL-12p70  –  modulated cells). These cells also included 
a signifi  cant population of IFN-     producers. 
  The spatial distribution of leukocytes within the spinal 
cord diff  ered consistently between the two groups. Infl  amma-
tory infi  ltrates were restricted to the meninges and subpial white 
matter in sections analyzed from recipients of IL-12  –  modu-
lated cells (  Fig. 2 C  , top). In contrast, infi  ltrating leukocytes 
typically extended from the subpial surface deep into the 
white matter parenchyma in recipients of IL-23  –  modulated 
cells (  Fig. 2 C  , bottom). In addition, optic nerve infl  ammation 
was more severe in the recipients of IL-23  –  modulated cells 
based on a signifi  cantly higher number of infi  ltrating cells 
per section (  Fig. 2 D  ). Brainstem infl  ammation was scant in 
both groups and consisted of occasional perivascular infi  l-
trates (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20080159/DC1). 
  Neutrophils are a conspicuous component of CNS infi  ltrates 
in mice injected with IL-23  –  modulated, but not IL-12  –
  modulated, T cells 
  The cellular composition of CNS –  infi  ltrating cells in each group 
at peak EAE was determined by fl  ow cytometric analysis. 
    Figure 2.         IL-12  –   and IL-23  –  modulated T cells induce forms of EAE with distinct cytokine profi  les and histological characteristics.  
(A) RNA was isolated from spinal cords of the recipients of IL-12  –   and IL-23  –  modulated T cells at the time of peak disease. Cytokine mRNA levels 
were measured by real-time RT-PCR and normalized to GAPDH. The data are shown as fold increase over levels in naive cords. (B) Mononuclear cells 
were isolated from pooled spinal cords at peak EAE for measurement of cytokines by ELISPOT assay. (C) Representative spinal cord sections are from 
adoptive transfer recipients that were killed upon reaching a clinical score of 3. Bars: left, 200   μ  m; right, 50   μ  m. (D) Optic nerves from representative 
mice with a clinical score of 3 were fi  xed and stained with hematoxylin and eosin. Histological scores were calculated from a total of 25 sections 
(obtained from 10 optic nerves) per group using ImageJ software. Bar, 100   μ  m. **, P   <   0.001; *, P   <   0.05 compared with recipients of IL-12  – 
modulated cells.     1538 IL-12 AND IL-23 INDUCE DISTINCT TYPES OF EAE   | Kroenke et al. 
but not IL-12  –  modulated, T cell lines (  Fig. 5 A  ).   This result 
supports our contention that Th17 cells and/or IFN-    /IL-17 
double producers within the IL-23  –  modulated cell lines are 
critical for disease transfer. Furthermore, it indicates that EAE 
induced by IL-12  –  modulated cell lines is not mediated by a 
contaminating subset of Th17 cells. 
  GM-CSF is induced by Th17 cells and drives myeloid cell 
mobilization and diff  erentiation during infl  ammation (  18  ). 
GM-CSF plays a critical role in the development of EAE in 
MOG  35  –  55    –  immunized C57BL/6 mice because its defi  ciency 
or neutralization results in resistance (  19  ). Within our experi-
mental paradigm, we found that GM-CSF neutralization is 
selectively eff  ective for the suppression of EAE induced by 
IL-23  –  modulated cells (  Fig. 5 B  ). 
  Th1 cells frequently secrete TNF-    . In addition, TNF-     
acts synergistically with IL-17 to trigger cytokine expression 
and to promote autoimmune responses in animal models of 
arthritis (  18  ). Neutralization of TNF-     has been shown to 
have benefi  cial as well as disease-exacerbating eff  ects in EAE 
depending on the particular model used and the timing of 
antibody administration (  20, 21  ). As illustrated in   Fig. 5 C  , 
administration of a monoclonal antibody to TNF-     amelio-
rated disease in recipients of either IL-12  –   or IL-23  –  modu-
lated, PLP-reactive cells. In contrast, neutralization of IFN-     
did not suppress adoptively transferred EAE, regardless of 
the polarizing conditions used to generate encephalitogenic 
cell lines (  Fig. 5 D  ). In fact, animals treated with anti  –  IFN-     
CD11b  +   cells and large amounts of NOS2, a product of acti-
vated macrophages and microglia (  Figs. 3, B  –  D  , and   4 C  ). 
  Adoptive transfer of IL-12  –   and IL-23  –  modulated T cells 
induces distinct chemokine profi  les in the infl  amed CNS 
  The above fi  ndings suggest that IL-23 –  modulated, as opposed 
to IL-12p70  –  modulated, cells induce a CNS microenviron-
ment that is favorable for the accumulation of neutrophils. 
Because the cellular composition of infl  ammatory infi  ltrates 
is infl  uenced by local chemokine production, we compared 
CNS expression of a panel of chemokines in IL-12  –   and 
IL-23  –  driven EAE by real-time RT-PCR. Adoptive transfer re-
cipients of IL-23  –  modulated cells preferentially up-regulated 
the neutrophil-attracting ELR  +   CXC chemokines, CXCL1 
and CXCL2, in the brain and spinal cord (  Fig. 4 A   and not 
depicted). Conversely, recipients of IL-12  –  modulated cells 
preferentially up-regulated the monocyte- and lymphocyte-
attracting ELR        CXC chemokines, CXCL9, CXCL10, and 
CXCL11 (  Fig. 4 B  ). 
  Mice with EAE induced by IL-12  –   or IL-23  –  modulated 
T cells respond differently to specifi  c immunomodulatory 
interventions 
  We next questioned whether IL-12  –   and IL-23  –  driven forms 
of EAE would respond diff  erently to specifi  c immunomodu-
latory interventions. Administration of a neutralizing antibody 
against IL-17 blocked disease mediated by IL-23  –  modulated, 
    Figure 3.         CNS infl  ammatory infi  ltrates induced by IL-12  –   and IL-23  –  modulated T cells differ in cellular composition.   (A and B) Mice were 
killed at peak EAE, and fl  ow cytometry was performed on mononuclear cells isolated from pooled brains and spinal cords (fi  ve to six mice/group). Periph-
eral blood monocytes were analyzed in parallel. Plots in A are gated on class II        cells. (C and D) Absolute cell numbers were calculated as the product of 
the average number of CNS mononuclear cells harvested per mouse (pooled from brain and spinal cord) and the percentage of CD11b  +   class  II +   or 
Ly6G  + 7/4 +   cells (determined by fl  ow cytometry). The data shown are representative of three independent experiments.     JEM VOL. 205, July 7, 2008  1539
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extension, the variable responsiveness of patients with MS to 
therapy with IFN-     or glatiramer acetate might refl  ect diff  er-
ences in underlying immunopathogenic mechanisms. 
  There is growing evidence that myelin-specifi  c Th17 cells 
and/or IL-17/IFN-     double-producing cells are the critical 
effectors in EAE induced by the active immunization of 
C57BL/6 mice with MOG  35  –  55   (  8, 11, 25  ). Interestingly, ex-
pression of GM-CSF and IL-23p19, but not IL-12p35, is 
required for the manifestation of disease in this model (  8, 9, 19  ). 
IL-17 is a potent inducer of GM-CSF in a wide spectrum of 
cell types (  18  ). During EAE, GM-CSF could stimulate the 
mobilization and activation of monocytes that, in turn, pre-
sent myelin antigens to autoreactive T cells and provide a 
source of CNS-infi  ltrating macrophages. Our fi  nding that anti  –
  GM-CSF treatment was selectively eff  ective in suppressing 
IL-23  –  driven disease suggests that IL-12  –  driven disease invokes 
alternative, as of yet undiscovered pathways to recruit mye-
loid cells into the pathogenic process. 
  It could be argued that the histopathological and immuno-
logical features of IL-23  –  driven EAE are more reminiscent of 
rare variants of autoimmune demyelination, such as Marburg  ’  s 
disease, acute disseminated encephalomyelitis, and neuromye-
litis optica, as well as the opticospinal form of MS that has been 
described in Asia. Each of those conditions is characterized 
by the presence of neutrophils in white matter lesions (  27, 28  ). 
Elevated levels of IL-8 (in the same family as CXCL1 and 
CXCL2) have been detected in the cerebrospinal fl  uid of 
tended to experience a more severe course. The latter result 
is consistent with previously published studies demonstrating 
that IFN-     defi  ciency paradoxically increases susceptibility 
to autoimmune CNS demyelination, even in models that 
are IL-12p40 or IL-12p70 dependent (  10  ). We have found 
that IL-12 directly stimulates myelin-reactive T cells to up-
regulate P-selectin ligand and CCR5 by IFN-      –  independent 
pathways, thereby facilitating CNS homing (  22, 23  ). On the 
other hand, a Th1-driven model of uveitis, elicited with ret-
inal antigen-pulsed dendritic cells, is dependent on recipient-
produced IFN-     (  24  ). Hence, even among Th1-mediated, 
organ-specifi  c autoimmune diseases, cytokine requirements 
are variable. 
  It has long been proposed that autoimmune demyelinat-
ing disease and even   “  garden-variety  ”   relapsing-remitting MS 
represent a spectrum of conditions with distinct pathophys-
iological etiologies but a common clinical outcome (  26  ). Our 
experiments provide   “  proof of principle  ”   in demonstrating 
that IL-12  –   and IL-23  –  modulated cells transfer a clinically 
indistinguishable ascending myelitis by using distinct pro-
infl  ammatory pathways based on CNS chemokine, cytokine, 
and eff  ector molecule profi  les and on the cellular composition 
and spatial distribution of infl  ammatory infi  ltrates. Most strik-
ingly, the two forms of EAE respond diff  erently to specifi  c 
immunomodulatory interventions; neutralization of either 
GM-CSF or IL-17 suppressed EAE induced by IL-23  –  mod-
ulated, but not IL-12  –  modulated, myelin-specifi  c T cells. By 
    Figure 4.         IL-12  –   and IL-23  –  modulated T cells induce distinct panels of chemokines and effector molecules in the CNS.   Real-time  RT-PCR 
was performed using RNA isolated from individual spinal cords at peak disease. Levels of ELR  +   CXC chemokines (A), ELR        CXC chemokines (B), and G-CSF 
and NOS2 (C) were normalized to GAPDH and averaged over four to six mice per group. The data shown are representative of three independent experi-
ments. **, P   <   0.001; *, P   <   0.05 by comparison to recipients of IL-12  –  modulated T cells.     1540 IL-12 AND IL-23 INDUCE DISTINCT TYPES OF EAE   | Kroenke et al. 
  MATERIALS AND METHODS 
  Mice.     6  –  8-wk-old female SJL/J mice were obtained from NCI Frederick and 
housed in microisolator cages. All animal protocols were approved by the 
University of Michigan Committee on Use and Care of Animals. 
  Immunization and T cell culture.     Mice were injected s.c. with 100   μ  g 
PLP  139  –  151   HSLGKWLGHPDKF (Quality Controlled Biochemicals) in IFA 
(Difco). Draining LNs were harvested 10  –  14 d later and passed through a 70-  μ  m 
cell strainer (BD Falcon). LNCs were cultured in vitro for 4 d with PLP  139  –  151   
under conditions favorable to the generation of either Th1 cells (5 ng/ml 
rmIL-12, 2 ng/ml rmIFN-    , 10   μ  g/ml     IL-4 [clone 11B11], and 10   μ  g/ml 
    IL-23 p19 [CNTO209]) or Th17 cells (5 ng/ml rmIL-23, 10 ng/ml IL-1    , 
25   μ  g/ml     IFN-     [AN18], and 10   μ  g/ml     IL-4). Other cells were cultured 
with antigen under neutral conditions (10   μ  g/ml     IL-12 p40 [C17.8]). Mouse 
    IL-23p19 and     IL-17 were provided by J. Benson (Centocor). 
  ELISPOT assays.     CNS cells were cultured for 24 h in 96-well fi  ltration 
plates (MAIP N4550; Millipore) at 7.5   ×   10  3   cells/well in triplicate, with or 
without 50   μ  g/ml PLP  139  –  151  . Spots were counted using the CTL Immuno-
Spot Analyzer (Cellular Technology) with ImmunoSpot software. 
  Induction of EAE and immunomodulatory treatment.     LNCs were 
harvested after 4 d of in vitro culture. CD4  +   T cells were isolated via comple-
ment-mediated depletion of class II  +   (clone BP107), CD24  +   (clone J11D), and 
CD8  +   cells (clone 3.155). Fico/Lite (Atlanta Biologicals) was then used to 
isolate live cells. CD4  +   T cells (25   ×   10  6   in 0.2 ml sterile PBS; 85  –  95% pure) 
were injected i.p. Mice were observed on a daily basis for signs of EAE and 
scored as described previously (  10  ). Mean clinical scores were compared using 
Student  ’  s   t   test. The following antibodies were used for in vivo neutralization: 
anti  –  IL-17 (clone CNTO5824), anti  –  IFN-     (XMG1.2), anti  –  GM-CSF 
(22E9.11), and anti  –  TNF-     (TN3-19). Rat IgG (Sigma-Aldrich) was used as 
a control for anti  –  IL-17, anti  –  IFN-    , and anti  –  GM-CSF. Armenian hamster 
IgG (eBioscience) was used as a control for anti  –  TNF-    . The neutralizing 
effi   cacy of anti  –  IFN-     monoclonal antibodies in vivo was demonstrated by 
suppression of CXCL9 mRNA in the spleen as measured by real-time RT-
PCR (P   <   0.01) (unpublished data). 
  RT-PCR.     CNS tissues were homogenized in Trizol reagent (Invitrogen). 
RNA was isolated and cDNA was synthesized using a Quantitect reverse 
  transcription kit (QIAGEN). Primers and probes were designed using Beacon 
Designer and synthesized by Integrated DNA Technologies. For ROR    t, 
a previously published primer/probe set was used (  29  ). Samples were ana-
lyzed on an iCycler PCR machine (Bio-Rad Laboratories). All data were 
normalized to GAPDH and expressed as fold induction over naive unless 
otherwise stated. REST 2005 software was used to analyze data and determine 
statistical signifi  cance. 
  Flow cytometry.     Brain and spinal cord were harvested at peak disease, ho-
mogenized in 1 mg/ml DNase and 2 mg/ml collagenase, and incubated for 
1 h at 37  °  C. Mononuclear cells were then isolated over a 30/70% Percoll 
gradient (GE Healthcare). Flow cytometry was performed using a BD 
FACSCalibur. 
  Histological staining and analysis.     Paraformaldehyde-fi  xed CNS and 
optic nerve sections were stained with hematoxylin and eosin using standard 
protocols (  10  ). Optic nerve sections were imaged and analyzed using ImageJ 
software. Histological sections were scored by an investigator blinded to 
experimental group as follows: 0, no infi  ltration (  <  50 cells); 1, mild infi  l-
tration of nerve or nerve sheath (50  –  100 cells); 2, moderate infi  ltration 
(100  –  150 cells); 3, severe infi  ltration (150  –  200 cells); 4, massive infi  ltration 
(  >  200 cells). 
  Online supplemental material.     Fig. S1 shows perivascular infi  ltrates in 
the mesencephalon of representative mice with EAE mediated by IL-12  –   or 
IL-23  –  modulated myelin-specifi  c T cells. 
  patients with the opticospinal variant (  28  ). Interestingly, both 
the opticospinal variant and Devic  ’  s disease specifi  cally target the 
spinal cord and optic nerves, and IL-23  –  driven EAE is mani-
fested by myelitis with severe optic neuritis. 
  On the other hand, IL-12  –  driven EAE more closely re-
sembles conventional relapsing-remitting MS in the promi-
nence of activated macrophages and dearth of neutrophils in 
CNS infi  ltrates and preferential up-regulation of the chemo-
kines CXCL9, CXCL10, and CXCL11. Our study has im-
portant implications with regard to the future use of agents 
that target specifi  c cytokines, chemokines, or eff  ector mole-
cules in MS and related infl  ammatory demyelinating disease. 
It is likely that immunomodulatory regimens will have to be 
customized based on the dominant Th eff  ector pathways that 
underlie each individual patient  ’  s condition. 
    Figure 5.         EAE mediated by IL-12  –   or IL-23  –  polarized T cells re-
sponds differently to specifi  c immunomodulatory interventions.  
Adoptive transfer recipients were injected with neutralizing antibodies 
specifi  c for IL-17 (A), GM-CSF (B), TNF-     (C), IFN-     (D), or isotype control. 
Antibody injections were given either every 4 d (A, C, and D) or every 2 d 
(B) from day 4 after transfer (0.4 mg/dose). Each treatment group con-
sisted of fi  ve to seven mice. Data shown are representative of two or 
more experiments with similar results. **, P   <   0.005; *, P   <   0.05 compared 
with the group treated with isotype control.     JEM VOL. 205, July 7, 2008  1541
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